Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090721 · ClinicalTrials.gov registry record · Phase 3
DMT310-009 Topical in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
NCT06090721 is a Phase 3 study that has completed, run by Dermata Therapeutics. The registered enrollment target is 520 participants.
The verdict
NCT06090721, a Phase 3 study, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
Study Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
Interventions
- DRUG Placebo
- DRUG DMT310
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06090721
The ClinicalTrials.gov registry entry for NCT06090721 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dermata Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06090721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06090721 about?
NCT06090721 is a clinical study titled "DMT310-009 Topical in the Treatment of Acne Vulgaris". The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
What is the current status of trial NCT06090721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2023-12-08. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06090721?
The interventions under investigation include: Placebo (DRUG), DMT310 (DRUG).
Who is sponsoring clinical trial NCT06090721?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.